Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444661 | 0.83 | HTT (0.63) | HTTSMN1; SMN2PKMCTSSMEN1 | |
| SCHEMBL6442796 | 0.75 | HTT (0.50) | HTTSMN1; SMN2PKMCTSSNPC1 | |
| SCHEMBL6442801 | 0.75 | HTT (0.50) | HTTSMN1; SMN2PKMCTSSNPC1 | |
| Valine SCHEMBL27915555 | 0.74 | SLC7A5 (0.56) | SMN1; SMN2PKMSLC7A5RAB9AALDH1A1 | |
| SCHEMBL13584805 | 0.73 | HTT (0.54) | HTTSMN1; SMN2PKMCTSSMEN1 | |
| SCHEMBL13584807 | 0.73 | HTT (0.54) | HTTSMN1; SMN2PKMCTSSMEN1 | |
| Valine SCHEMBL8711824 | 0.71 | SLC7A5 (0.75) | SMN1; SMN2PKMSLC7A5ALDH1A1 | |
| SCHEMBL1769490 | 0.71 | HTT (0.53) | HTTSMN1; SMN2PKMMEN1KMT2A | |
| SCHEMBL1769493 | 0.71 | HTT (0.53) | HTTSMN1; SMN2PKMMEN1KMT2A | |
| SCHEMBL13754285 | 0.71 | HTT (0.65) | HTTSMN1; SMN2PKMCTSSNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | HTT 55/4885SMN1; SMN2 1200/4885PKM 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.